Psoriasis
News
Biologics curb coronary artery plaques in severe psoriasis
Treating psoriasis with biologics improves coronary plaque profiles, suggesting an impact on inflammation and opportunity to reduce cardiovascular...
News
Different disease features found with family history of psoriasis versus PsA
The finding suggests different genetic backgrounds and pathogenic mechanisms in these subsets.
Conference Coverage
Guselkumab tops secukinumab over 48 weeks for plaque psoriasis
CAYMAN ISLANDS – In both groups, the PASI 90 increased similarly in the first month, but was consistently higher in the guselkumab group at week...
Conference Coverage
Comorbidities may cut effectiveness of psoriasis biologics
PARIS – In the PSO-BIO-REAL study, PASI 100 rate dropped as the number of comorbidities rose.
Conference Coverage
Brodalumab raced past ustekinumab to PASI 100
PARIS – Pooled analysis of phase 3 trials spotlights one clinical setting where brodalumab is particularly advantageous.
Conference Coverage
Longterm maintenance of PASI 75 responses observed with tildrakizumab
PARIS – More than 90% of PASI 75 responders to tildrakizumab at 6 months maintained at least a PASI 75 response at 148 weeks.
Conference Coverage
CONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologics
PARIS – Results of the first-ever randomized trial of biologic dose reduction in well-controlled psoriasis patients are reported.
News
Algorithm proposes approach for managing TNF inhibitor–induced psoriasis
Conference Coverage
Weight loss cuts risk of psoriatic arthritis
CHICAGO – An empowering new message for psoriasis patients.
Conference Coverage
Comorbidities are important in psoriasis care
LAS VEGAS – Cardiovascular comorbidities and psoriatic arthritis top the list of issues to keep an eye on.